AZNAstraZenecaSigning up patients
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 278 (planned)
- Started
- Aug 7, 2025
- Main results expected
- Apr 6, 2029
- Fully finished
- Apr 6, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AE) and serious adverse events (SAE)
Measured over: Through study completion, an average of 3 years
Objective response rate (ORR)
Measured over: Through study completion, an average of 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07098338 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC